ArticleMolecules (Basel, Switzerland)2010
Development of a sphingosylphosphorylcholine detection system using RNA aptamers.
Article in Molecules (Basel, Switzerland), 2010. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
13 citing papers in PubMed, 17 citations in OpenAlex.
- Selective Label-Free Detection of Imidacloprid by a Graphene Quantum Dot Fluorescent Probe.International journal of molecular sciences · 2025Article
- Oligomeric amyloid-β targeted contrast agent for MRI evaluation of Alzheimer's disease mouse models.Frontiers in pharmacology · 2024Article
- Article
- SELEX tool: a novel and convenient gel-based diffusion method for monitoring of aptamer-target binding.Journal of biological engineering · 2020Article
- Review
- Label-Free G-Quadruplex Aptamer Fluorescence Assay for Ochratoxin A Using a Thioflavin T Probe.Toxins · 2018Article
- NMR monitoring of the SELEX process to confirm enrichment of structured RNA.Scientific reports · 2017Article
- Selection, Characterization and Application of Artificial DNA Aptamer Containing Appended Bases with Sub-nanomolar Affinity for a Salivary Biomarker.Scientific reports · 2017Article
- Selection and Biosensor Application of Aptamers for Small Molecules.Frontiers in chemistry · 2016Review
- Sphingosylphosphorylcholine in cancer progress.International journal of clinical and experimental medicine · 2015Review
- Identification and characterization of a mirror-image oligonucleotide that binds and neutralizes sphingosine 1-phosphate, a central mediator of angiogenesis.The Biochemical journal · 2014Article
- Challenges and opportunities for small molecule aptamer development.Journal of nucleic acids · 2012Article
- ValFold: Program for the aptamer truncation process.Bioinformation · 2011Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Sphingosylphosphorylcholine (SPC) is a lysosphingolipid that exerts multiple functions, including acting as a spasmogen, as a mitogenic factor for various types of cells, and sometimes as an inflammatory mediator. Currently, liquid chromatography/tandem mass spectrometry (LC/MS/MS) is used for the quantitation of SPC. However, because of the complicated procedures required it may not be cost effective, hampering its regular usage in a routine practical SPC monitoring. In this report, we have generated RNA aptamers that bind to SPC with high affinity using an in vitro selection procedure and developed an enzyme-linked aptamer assay system using the minimized SPC aptamer that can successfully distinguish SPC from the structurally related sphingosine 1-phosphate (S1P). This is the first case of the Systematic Evolution of Ligands by EXponential enrichment (SELEX) process being performed with a lysosphingolipid. The SPC aptamers would be valuable tools for the development of aptamer-based medical diagnosis and for elucidating the biological role of SPC.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.